European drug regulators have recently concluded that there is no evidence linking popular diabetes and weight-loss drugs like Ozempic and Wegovy to a higher risk of suicidal thoughts or actions. The European Medicines Agency regulatory committee announced the results of its review, joining the U.S. Food and Drug Administration in this assessment.
In January, the FDA stated that a preliminary review showed no evidence of a link between these drugs and suicide, although it acknowledged the possibility of a small risk. A U.S. study funded by the government also found that individuals taking semaglutide, the active ingredient in Ozempic and Wegovy, had a lower risk of suicidal thoughts compared to those using older medications for diabetes and obesity.
The European Union's regulatory review was prompted by anecdotal reports last July suggesting that individuals taking these drugs experienced thoughts of self-harm. The regulators thoroughly examined various studies, post-marketing data, and other research related to nearly a dozen medications used to treat diabetes and obesity.
It is important to note that the review did not cover information regarding tirzepatide, the active ingredient in drugs marketed as Mounjaro and Zepbound. Both the European and U.S. regulatory bodies have committed to closely monitoring reports of suicidal thoughts or actions in individuals using GLP-1 receptor agonists, the drug class to which Ozempic and Wegovy belong.
Officials advise patients taking these medications to promptly report any mental health or other issues to their healthcare providers. The regulatory agencies will continue to investigate and assess any potential risks associated with these drugs to ensure the safety and well-being of patients.
It is reassuring for patients and healthcare providers alike to know that current evidence does not suggest a link between these widely used diabetes and weight-loss drugs and an increased risk of suicidal thoughts or actions.
